EyePoint, Inc. (EYPT) SEC Filings, May-Jul 2026

An affiliate of EYPT filed to potentially sell 1,235 shares of common stock through Fidelity Brokerage Services on the NASDAQ. The intended sale date is July 22, 2026, with an indicated aggregate market value of $15,820.00. These shares relate to stock options originally granted on February 21, 2022 as compensation.

EYPT received a notice of intent to sell 421,235 shares of common stock through Fidelity Brokerage Services on or after July 21, 2026 on the NASDAQ market. The filing lists an aggregate market value for these shares of $5,497,116.75.

The issuer reports 83,841,298 shares outstanding. The shares to be sold are tied to multiple stock option grants received as compensation from 2020 through 2026, each with specific grant dates and share amounts.

EyePoint, Inc. entered into a Settlement Agreement with the U.S. Department of Justice, OIG-HHS, the Defense Health Agency and a relator to resolve potential civil claims arising from alleged sales, marketing and sampling practices for DEXYCU® from 2019 to 2023. The company will pay a total settlement amount of $4,678,981.86, plus interest at 4.25% per annum from January 28, 2026, allocated between the United States and certain participating states, within 14 days of July 17, 2026, and will pay $166,500 in relator attorneys’ fees within 60 days, using cash on hand.

Upon payment, government agencies and the relator will release EyePoint and dismiss the related civil action, without any admission of liability by the company. Separately, EyePoint entered into a five-year Corporate Integrity Agreement with OIG-HHS effective July 13, 2026, requiring enhanced healthcare compliance structures, independent reviews, employee screening and training. In exchange, OIG-HHS agreed not to seek EyePoint’s exclusion from Medicare, Medicaid or other federal health care programs for the Covered Conduct, though future noncompliance with the agreement could lead to monetary penalties or program exclusion.

EyePoint, Inc. President and CEO Jay S. Duker exercised 16,667 restricted stock units into common stock on July 10, 2026. No shares were sold; 8,059 shares were withheld by the issuer to satisfy tax obligations, leaving him with 9,594 shares held directly. A Family Trust for his children holds 177,431 shares, and he disclaims beneficial ownership of those trust holdings.

EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported an option exercise-and-sale transaction in company stock. On June 30, 2026, he exercised options to acquire 4,875 shares of common stock at an exercise price of $8.26 per share, then sold 2,438 shares at a weighted average price of $15.0172 and 2,437 shares at $15.00 in open-market sales. Following these trades, his directly held common stock position was 0 shares, while his stock option holdings increased to 78,001 options with an exercise price of $8.26 expiring on January 3, 2035. A related footnote explains that 25% of this option grant vests on January 3, 2026, with the remainder vesting monthly over the following three years.

EyePoint, Inc. reported results from its 2026 Annual Meeting of Stockholders held via live webcast. Stockholders approved an amendment to the 2023 Long-Term Incentive Plan, increasing the shares of common stock authorized for issuance under the plan by 4,900,000 shares.

As of the April 21, 2026 record date, 83,795,203 shares were outstanding, and 71,010,327 shares, or 84.74%, were represented to constitute a quorum. Stockholders elected all nominated directors, approved on an advisory basis the compensation of named executive officers, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

EyePoint, Inc. Schedule 13G reports that Commodore Capital and related filers beneficially own 4,250,000 shares of EyePoint common stock as of May 27, 2026. The filing states this represents 5.1% of the class using 83,841,298 shares outstanding as of May 1, 2026.

The report clarifies the Firm is the investment manager to Commodore Capital Master LP and that Michael Kramarz and Robert Egen Atkinson are managing partners exercising investment discretion. The filing is a joint statement and includes a signed Joint Filing Agreement.

EyePoint, Inc. Chief Financial Officer George Elston reported routine equity compensation activity involving common stock and restricted stock units. He exercised 7,500 restricted stock units into 7,500 shares of common stock. Of these, 3,627 shares were withheld by EyePoint to cover tax obligations, and no shares were sold in the market.

Following these transactions, Elston holds 91,691 shares of common stock directly. In addition, 30,000 shares of common stock are held indirectly through a family trust for the benefit of his children, for which he disclaims beneficial ownership.

Paradigm BioCapital Advisors and related reporting persons filed Amendment No. 1 to a Schedule 13G/A reporting their beneficial ownership in EyePoint, Inc. The filing lists Paradigm BioCapital Advisors and Senai Asefaw, M.D. as reporting persons and shows specific share counts and ownership percentages as of March 31, 2026.

The statement reports 3,142,437 shares (3.8%) beneficially owned by Paradigm BioCapital Advisors (and affiliated GP/individual) and 2,769,062 shares (3.3%) held by Paradigm BioCapital International Fund Ltd. The filing cites 83,453,001 shares outstanding as of March 31, 2026 per the issuer's Form 10-Q filed May 7, 2026.